Building Relationships with Scientific Partners Connects Families to Research
Conquering CHD is committed to research that matters. Thank you to Prolacta Bioscience for sharing information on the clinical trial researching human milk diets for single ventricle infants.
Through our collaborative relationship with Prolacta Bioscience, Conquering CHD has been closely following a clinical trial researching an exclusive human milk diet for single ventricle infants. In April, Prolacta announced that patient enrollment was complete and the trial included 107 infants from nine centers in Texas, Ohio, Oklahoma, California, Illinois, New York, and Florida. The trial is being led by principal investigator Dr. Cynthia Blanco of University of Texas Health.
The Exclusive Human Milk Feeding in Infants With Single Ventricle Physiology trial is a randomized, blinded, controlled trial to evaluate growth velocity and clinical outcomes in infants with single ventricle physiology fed an exclusive human milk diet prior to, and throughout the post-operative period following surgical repair.Taken from clinicaltrials.gov
Translation: Can clinicians improve growth and outcomes of single ventricle babies by feeding them only human milk before and after surgery, and during the recovery period?
Why is this trial important? Single ventricle babies face a host of potential complications, including slow growth, feeding intolerance, and necrotizing enterocolitis (NEC). The trial proposes that feeding these infants a human milk only diet will have both short- and long-term benefits.
When will the results of the clinical trial be available to the public? Initial data, presented at an academic conference this May, show a lot of promise. Stay tuned as we anticipate final trial results by the end of 2021.
Will Conquering CHD update the community when new information is available? Yes! An informative webinar is in the works.
Where can I learn more? Review the trial’s publicly available details here.
About Prolacta Bioscience
Prolacta Bioscience® Inc. is a privately-held life sciences company dedicated to Advancing the Science of Human Milk®. Prolacta is the world’s leading hospital provider of 100% human milk-based nutritional products. These life-saving products have reduced complications and improved the health of more than 63,000 extremely premature infants globally. In addition, the company is exploring the therapeutic potential of human milk across a wide spectrum of human diseases, including applications for infants requiring surgery for congenital cardiac and gastrointestinal disorders. Operating the world’s first pharmaceutical-grade human milk processing facilities, Prolacta leads the industry with the highest quality and safety standards for the screening and testing of donor milk. Prolacta is a global company with headquarters in Duarte, California, and can be found online at www.prolacta.com, Twitter, Instagram, Facebook, www.facebook.com/prolacta, and LinkedIn.